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Human glutathione transferases (GSTs) are a multigene family of enzymes that are involved in the
metabolism of a wide range of electrophilic compounds of both exogenous and endogenous
origin. GSTs are generally recognized as detoxifying enzymes by catalyzing the conjugation of
these compounds with glutathione, but they may also be involved in activation of some
carcinogens. The mammalian GSTs can be differentiated into four classes of cytosolic enzymes
and two membrane bound enzymes. Human epoxide hydrolases (EHs) catalyze the addition of
water to epoxides to form the corresponding dihydrodiol. The enzymatic hydration is essentially
irreversible and produces mainly metabolites of lower reactivity that can be conjugated and
excreted. The reaction of EHs is therefore generally regarded as detoxifying. The mammalian EHs
can be distinguished by their physical and enzymatic properties. Microsomal EH (mEH) exhibits a
broad substrate specificity, while the soluble EH (sEH) is an enzyme with a "complementary"
substrate specificity to mEH. Cholesterol EH and leukotriene A4 hydrolase are two EHs with very
limited substrate specificity.The activities of either GSTs or EHs expressed in vivo exhibit a
relatively large interindividual variation, which might be explained by induction, inhibition, or
genetic factors. These variations in levels or activities of individual isoenzymes are of importance
with respect to an individual's susceptibility to genotoxic effects. This article gives a general
overview of GSTs and EHs, discussing the modulation of activities, determination of these
enzymes ex vivo, and the polymorphic expression of some isoenzymes. Environ Health
Perspect 105(Suppl 4):791-799 (1997)
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Introduction
Epidemiological evidence indicates that
most ofour human cancers are originally
caused from environmental exposures to
genotoxic agents. It is estimated that as
much as two-thirds ofall human cancers
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are caused from exposures to tobacco
smoke and dietary components (1). To be
able to protect cells from damage by the
exposure ofvarious forms of reactive sub-
stances, cellular systems for detoxification
are essential. Two major systems that
strongly regulate the susceptibility to, e.g.,
cancer have been identified, namely the
enzymes involved in drug metabolism and
in DNA repair. Since most carcinogens or
mutagens need to be altered chemically by
drug-metabolizing enzymes (2) before they
can exert their genotoxic effect, the impor-
tance of these enzymes in regulating the
levels ofinduced genotoxic effect in cells is
obvious. The cytochrome P450 system is
able to metabolize a various number of
xenobiotics to highly reactive intermediates
such as epoxides, which can bind covalently
to cellular components. The enzymatic
conversion ofthese epoxides to less reactive
intermediates is protective and occurs by
spontaneous conjugation with glu-
tathione (GSH) or enzymatic conjugation
by glutathione transferases (GSTs), as
well as by hydration to the corresponding




Glutathione transferases (GSTs) are a
complex multigene family ofenzymes that
possess many biological functions such as
the important step in detoxification of a
large number ofelectrophiles. Such conju-
gation reactions result in the synthesis of
mercapturic acids and represent an impor-
tant excretory route for many xenobiotics
(5,6). For some classes of substrates, the
initial conjugates are broken down by a
second reaction with glutathione (GSH).
One example is organic hydroperoxides (7)
and ozonides (8), in which in addition to
glutathione, disulfide (GSSG), an alcohol,
is formed. Another example is alpha-
halogeno ketones (9), in which halogen is
replaced by hydrogen in addition to the
formation GSSG. These examples are
shown in Figure 1.
Although GSTs are generally recog-
nized as detoxifying enzymes, they may
also be involved in activation processes of
some carcinogens such as haloalkanes and
haloalkenes (10,11). It has been shown
that GSTs can catalyze the formation of
an episulfonium ion via ethylene
dibromide and GSH. If this reactive
intermediate is formed, it will react with
nucleophiles such as water, GSH, or
guanine in DNA (Figure 2).
Cytosolic GSTs are dimeric proteins
with an approximate molecular weight of
25,000 Da for each subunit. The largest
amount of GST protein is present in the
liver, representing 3 to 5% oftotal soluble
proteins (12). The mammalian GST can
be separated into four classes, based on
substrate specificity, immunological iden-
tity, protein, and DNA sequence. The dif-
ferent classes comprise alpha, mu, pi, and
theta. The structural similarity of the
amino acid sequence identity among










3. R-CO-CH2-X + GSH->R-CO-CH2-SG + XH
R-CO-CH2-SG + GSH-R-CO-CH3 + GSSG
Figure 1. GST reaction pathways for the conjugation
ofxenobiotics with GSH.
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BrCH2CH2Br + GSH - * BrCH2CH2SG - H2C CH2 + Br-
Figure 2. Reaction of 1,2-dibromoethane with GSH to form episulfonium ion.
less than 25% identity between members
ofdifferent classes.
Structurally unrelated to the cytosolic
GSTs are two exclusively membrane-
bound proteins, microsomal GST and
leukotriene C4 synthase, which may have
arisen by convergent evolution (13).
Nomendat andCl(ification
ofGlutathioneTranserase
A variety of nomenclature systems for
GSTs have been proposed by several inves-
tigators over a number ofyears. Recendy, a
unifying nomenclature for human GSTs
has been proposed (Table 1) (14).
TheAlphaClass
GlutaioneTnserase
Among the alpha gene family, five human
GST isoenzymes have been identified
(15-17) that are present on chromosome
6pl2 (may include some pseudogenes). Of
these, at least GSTA1 and GSTA2 are
widely expressed in human tissues but their
expressions are subject to a marked varia-
tion. Thus, levels ofGSTA1 and GSTA2
may vary considerably between different
tissues and individuals (18). The alpha
class isoenzymes are strongly expressed in,
e.g., liver, kidney, and adrenal tissue.
However, it has been reported that this
alpha class of isoenzymes is not expressed
in these organs in some individuals (19).
This genetically determined deficiency is
believed to be extremely rare. An appar-
ently common restriction fragment length
polymorphism (RFLP) of GSTA2has been
reported (20). The significance of this
polymorphism is still unknown.
Characteristic properties of the alpha
class GSTs include, besides conjugation of
various agents with GSH, isomerization of
different ketosteroids and the nonselenium-
dependent GSH peroxidase activity towards
organic hydroperoxides (21). A different
form, other than the liver isoenzymes of
alpha class GST, has been identified in
human skin (16,17) which exhibits a con-
siderably high peroxidase activity. Since
ultraviolet light is known to cause lipid per-
oxidation in liposomal membranes, it is
likely that the expression of this "skin"
GST can contribute to the protection of
these cells against the oxidative stress.
Compared with other GSTs, GSTA2 has
been shown to exhibit the highest activity
towards the recently discovered 9,10-
methyl-linolate ozonide, which is postu-
lated to be the intermediate in the toxicity
ofozone (8). The alpha class GSTs appear
also to be the major GST isoenzyme
responsible for the hepatic binding of
bilirubin and other organic anions (22).
TheMuClass Glutadbione
Transferase
Five genes ofthe mu class GST, numbered
MI to M5, have been identified in humans
(23,24). These genes occur as a cluster on
chromosome 1p13 (23,24). The expres-
sion ofthese genes exhibits a comparatively
large between-tissue variation. The most
Table 1. Nomenclature for human GSTs.
Enzyme Gene
Currentdesignation Class Some previous designations Locus designation Chromosome band
GSTAl-1 Alpha e, B1 B1 GST2-type 1 GSTA 1 6pl2
GSTA2-2 Alpha y, B2 B2, GST2-type 2 GSTA 2 6pl2
GST Mla-la Mu p, GST1-type 2 GSTM 1 lp13
GST Mlb-lb Mu if, GST1-type 1 GSTM 1 1p13
GST M2-2 Mu GST4 GSTM2 1p13
GST M3-3 Mu GST 5 GSTM3 1pl3
GST M4-4 Mu GSTM4 lp13
GST M5-5 Mu GSTM5 1pl3
GSTPl-1 Pi x, GST3 GSTP 1 1lql3





commonly expressed gene is GSTMI,
which has a similar expression pattern to
that of the alpha class isoenzymes.
GSTM2 is more restricted to skeletal mus-
cle, as is GSTM3, which also has been
found in brain, lung, and testis. GSTM4
has been found in a human lymphoblas-
toid cell line and GSTM5 is expressed in
the brain (25,26).
The most interesting aspect ofthe mu
gene family may be the genetic polymor-
phism noticed for GSTMI. This phenome-
non was first recognized in human liver,
where the isoenzyme GST p (previous des-
ignation) was expressed in onlyapart ofthe
population ofthe samples analyzed (27).
The expression of GSTMI has been shown
to be autosomal dominant inherited, and
between 40 and 60% ofmost populations
express GSTM1 (28). Two allelic variants
have been described for GSTMI, GSTM1a
and GSTMlb, with similar enzyme activity
towards substrates for GSTM1. It has been
shown that the cDNAs coding for these
variants only differs in one amino acid, at
the position 172 (29,30). The genetic poly-
morphism exhibited by GSTMI may be a
factor in determining an individual's sus-
ceptibility to the toxic effects ofvarious
xenobiotics. For example, the high activity
ofGSTM1 (aand b) towards many epoxide
metabolites from polycyclic aromatic
hydrocarbons (PAHs), which are generally
thought to possess considerable mutagenic
and carcinogenic potential, may be ofpar-
ticular significance (31). It has been sug-
gested, for example, that these isoenzymes
could serve as genetic markers in the sus-
ceptibility for certain forms ofcancer (32).
The deficiency of GSTMI has been shown
to increase the susceptibility to DNA-
adduct formation (33) and cytogenetic
damage (34).
Polymorphism among other GSTM
genes has not yet been investigated, even
though a minority (about 10%) has been
shown to fail to express GSTM3 in brain in
one study (25).
ThePi Class GlutathioneTransferase
Among the pi genes, GSTP1 has been
identified; this gene has been mapped on
chromosome 11q13 (35). This isoenzyme
appears to be the most widely distributed
enzyme of all GSTs and it is the most
abundant form in many tissues (36) except
in the liver, where the alpha and mu gene
families are highly expressed. However, in
the fetal liver the major GST form is a pi
class isoenzyme. Several cDNA clones have
been isolated (37) with only some minor
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differences, which probably represent
allelic variants of a single locus, rather
than transcripts of different genetic loci
(38). It remains to be determined whether
these differences contribute to individual
variations in activity.
The enzyme activity exhibits a large
interindividual variation that may be of
clinical significance. Several reports have
suggested a possible role for GSTP1 as a
general tumor marker, determined in
plasma (39,40). However, the appearance
ofGSTP1 in, e.g., human hepatic tumors
is not specific only to the preneoplastic
state, since this expression can also be seen
in cirrhotic liver patients (41).
TheThetaClass
GlutatbioneTransferase
This gene family is the most recently
identified GST gene. Two genes, GSTTI
and GSTT2, have been isolated from
human liver (42, 43). Their expression
seems to be widespread in humans, and it
might have a fundamental role that has
not been fully investigated.
The human GSTT1 isoenzyme has
attracted interest since Ketterer and col-
leagues (44) identified a null allele at this
locus. Since the enzyme catalyzes the
detoxification ofmonohalomethanes and
ethylene oxide in vitro, lymphocytes from
expressors of the gene appear to be pro-
tected against the sister chromatid
exchange (SCE) induced by these com-
pounds. It is possible that, like individuals
with GSTMI null genotype, homozygous
individuals for the GSTTI null allele will
have altered cancer risk. The frequency of
the null allele has been reported to be 30 to
40% in one study from Germany (45),
while in a Swedish population only 10%
expressed this null allele (46).
Since some ofthe lesions in DNA may
be peroxides, e.g., irradiation offree thymi-
dine, which gives a substantial yield of
thymidine hydroperoxides (47,48) and
since it has been shown that GSTT has a
considerably high activity towards these
DNA hydroperoxides, it is likely that
GSTT plays a protective role in this man-
ner. On the other hand, it can also be
assumed that the positive phenotype may
be more sensitive to exposure to halo-
genated solvents such as methylene chlo-
ride. This is converted into formaldehyde,




The microsomal GST appears to have an
evolutionary origin totally distinct from
that ofthe cytosolic GSTs. It is present in
the endoplasmic reticulum and in the
outer mitochondrial membrane and
consists of three subunits, each with a
molecular weight of 17,300 Da (50). It is
most abundant in the liver but some
studies have also shown the expression of
this enzyme in the lung. The cDNA for
this enzyme has been cloned and it seems
to be encoded as a single copy gene on
chromosome 12 (51). Of special interest
for the microsomal GST is the ability to
be activated in vitro by different sulfydryl
agents such as N-ethylmaleimide (NEM),
diethylmaleate, dithiopyridol, cystine, and
glutathione disulfide. The activation of
this enzyme can be up to 20-fold by
NEM towards the substrate 1-chloro-2,4-
dinitrobenzene (CDNB). The more pro-
nounced the activation process seems to
be the more reactive the substrates are.
No activation in vivo has yet been seen in
humans but it has been demonstrated in
the rat by CC14 and phorone, both of
which produce reactive oxygen radicals.
Acrolein, which itself is a product of
oxidative stress, has also been shown to
increase the microsomal GST activity
in vivo (52,53).
Leukotriene C4 synthase, an enzyme
that is quite specific for the conjugation of
Table 2. Specific activities (pmol/min/mg) of human GSTs with some selected substrates.
GST
Substrate Al-i A2-2 Ml-i M2-2 M3-3 M4-4 Pl-i T2-2 Microsomal
CDNB 80 80 180 220 7 1.4 105 ND 1.9(24)a
Ethacrynic acid 0.2 0.1 0.08 0.2 0.2 0.1 0.9 ND
Leukotriene A4 0.009 0.04 0.002
Styrene, 7,8-oxide 0.02 . 2.6 0.14
trans-Stilbene oxide 0.002 5.2 0.0003 0.0004 0.003 0.002
BP-4,5-oxide 0.05 0.9 0.13
BP, 7,8-diol-9,10-oxide 0.04 0.6 0.8
Cumene hydroperoxide 10 100 0.6 0.03 7 0.04(3)a
CDNB, 1-chloro-2,4-dinitrobenzene; BP, benzo[aJpyrene; ND, no detectable activity. rValues in parentheses are for
activated enzyme.
leukotriene A4 to leukotriene C4, and some
other dosely related lipid epoxides may not
take part in the cellular detoxification sys-
tem. A summary ofsome selected substrates
for different GSTs is shown in Table 2.
Glutathione
The reaction ofxenobiotics with GSH may
occur spontaneously or enzymatically by
GSTs as described above. Ifthe spontaneous
conjugation ofa specific electrophile with
GSH is the only meanswhereby a particular
electrophile can be detoxified, the concen-
tration ofGSH will be ofcritical impor-
tance for this detoxification process. Nearly
all cells contain GSH with varying concen-
trations, depending on the origin ofthe cell.
In certain cells, e.g., hepatocytes, the GSH
concentrations (5-10 mM) may vary
according to the circumstances. For exam-
ple, GSH may be depleted during starvation
or after heavy electrophile load, or the cells
may have levels higher than normal as the
result ofa rebound effect following a period
ofdepletion (54,55).
Epoxide Hydrolases
Epoxide hydrolases catalyze the addition
ofwater to an epoxide to form the vicinal
dihydrodiol, which almost always has the
trans-configuration. The enzymatic hydra-
tion is essentially irreversible and pro-
duces metabolites oflower reactivity that
can be readily conjugated and excreted.
Therefore the action of EHs is generally
regarded as detoxifying. A number of
EHs, which are characterized by unique
immunological properties, molecular
weights, and substrate specificities have
been identified.
Microsomal EpoxideHydolases
Microsomal EH (mEH) has been purified
to homogeneity from a number ofspecies
and tissues, including human liver. High
specific activity of mEH has also been
found in human brain. The presence of
several drug-metabolizing enzyme activities
in human brain microvessels, and particu-
larly the high activity of EH, suggests a
participation ofthese enzymes in the meta-
bolic blood-brain barrier (56). Relatively
high levels of mEH have also been found
in the human adrenal gland, suggesting
that the enzyme may be of particular
importance in this tissue (57). However,
very little cytochrome P450-catalyzed
metabolism of xenobiotica has been
demonstrated in the human adrenal (58).
Researchers have detected mEH in various
cell populations, for example in human
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lymphocytes (59), human blood resting
mononuclear leukocytes (60) and adult
human hepatocytes (61). It is also notable
that the level of mEH activity in human
liver is approximately 50% higher in men
than in women, while in extrahepatic
organs, such as lung and adrenal, mEH
activity is the same in both sexes. In kid-
ney, the activity is slightly higher in
women than in men (62).
The human mEH protein contains 455
amino acids. The mEH protein and nucleic
acid sequences in humans, rats, and rabbits
are evolutionary conserved, with similarities
between the relevant sequences exceeding
83 and 75%, respectively. Several cDNA
clones have been isolated (63) with varia-
tion at only two residues, amino acids 113
and 139. The amino acid variation, how-
ever, does not exert a primary influence on
catalytic function, but may affect the stabil-
ity ofthe mEH protein. The human gene
(EPHXI) has been localized to the long
arm ofchromosome 1 (64). The existence
ofa single functional mEH gene per hap-
loid genome in humans and rats has been
proposed (65). In contrast to the GSTs and
cytochrome P450s, an absence ofgenetic
complexity has been observed for mEH.
The mEH exhibits a broad substrate
specificity, ranging from simple aliphatics,
e.g., octene oxide, to large polycyclic
aromatic hydrocarbons, e.g., different
benzo[a]pyrene epoxides.
In addition, it has recently been sug-
gested that mEH might mediate the trans-
port of bile acids, such as taurocholate,
into hepatocyte smooth endoplasmic retic-
ulum vesicles (66) and that the protein can
exist in two orientations in the membrane.
SolubleEpoxideHydolases
Soluble EH (sEH) is an enzyme with a
complementary substrate specificity to
mEH and it seems to be present in all
species investigated. The specific substrate
is trans-stilbene oxide. Compared with
mEH, sEH appears to be more substrate
selective, unable to metabolize bulky
steroids and polycyclic aromatic hydrocar-
bons. There seems to be a large interindi-
vidual variation in the expression of sEH
that is much larger than for mEH.
It has been shown that sEH in human
lymphocytes decreases the induction of
SCE caused by trans-,B-ethyl styrene, which
is an in vitrosubstrate for sEH (67).
The cloning and expression of a
cDNA encoding sEH predicts a protein of
554 amino acids (62,640 Da). The
cloned sEH hydrolyzed cis-stilbene oxide
faster than it hydrolyzed trans-stilbene
oxide, a reverse ofthe activity profile seen
in sEH ofthe mouse (68). The enzymatic
activity was inhibited by phenylglycidols.
The gene (EPHX2) has been localized to
chromosomal region 8p21-p12 (69).
Under certain conditions, mEH seems
also to be present in the cytosol, where it
has been detected in rat and human liver
by using catalytic and immunochemical
assays. This enzyme, sEHPNSO, has been
purified from human liver cytosol (70).
CholesterolEpoxideHydolases
This enzyme is expressed in the micro-
somes as mEH but has a very limited sub-
strate specificity for certain steroids only. It
is present in all species so far investigated.
The specific substrate is cholesterol 5,6-
oxide, which, it has been suggested, is
formed during lipid peroxidation or ultra-
violet irradiation of the skin (71). The
level of cholesterol 5,6-oxide seems to
increase under certain pathological condi-
tions, such as ulcerative colitis, colon
cancer, and hypercholesterolemia (72).
LeukotrieneA4Hydrolase
This cytosolic enzyme has been purified
and characterized from various types of
blood cells. The enzyme has a very narrow
substrate specificity. The product of the
hydration ofleukotriene A4 (LTA4) is not
vicinal but rather a 5,12-diol (73). There
appears to be no immunological relation-
ship between LTA4 hydrolase and any
other EH characterized so far. A summary
of the different substrate specificities for





The activities of either GSTs or EHs
expressed in vivo exhibit a relatively large
interindividual variation, which might be
explained by induction, inhibition, or
genetic factors.
Induction
Several agents have long been known to
induce GST and EH. Most studies have,
however, been performed in rat and mouse
by using inducers such as phenobarbital,
carcinogens (3-methylcholanthrene, 2-
acetylaminofluorene) or antioxidants
(BHA, BHT), etc. The induction process
in humans is not fully understood in
detail, but the regulation of GST expres-
sion in humans and in rodents has been
reviewed by Rushmore and Pickett (74).
Phenobarbital and phenytoin have been
shown to be inducers ofthe mEH activity
in vivo (75).
Soluble epoxide hydrolase is induced
by a diverse group of compounds known
as peroxisome proliferators, including
clofibrate, as well as by common environ-
mental and dietary contaminants, such as
phthalate ester (76). At present, no in vivo
inducers have been found, either for
cholesterol EH or for LTA4 hydrolase.
Inhibition
A relatively large number of inhibitors of
GST are known. Some are very selective to
specific GSTs and have been used in that
manner to characterize individual isoen-
zymes in vitro (49). Whether the inhibi-
tion found in vitro with cytosolic fractions
or bypurified isoenzymes has any relevance
in vivo requires further studies. However, a
number of quinones have been shown to
be capable ofinhibiting GST activity in a
cellular system, indicating that inhibition
by these compounds is possible under
physiological conditions and might occur
in vivo. Misonidazole, a radiosensitizing
drug, has been shown to inhibit GST
activity in mouse liver in vivo (77). In
humans, ethacrynic acid and its analogs
interfere with hepatic GST, and a number
of antibiotics (penicillins and cephalo-
sporins) inhibit human GSTP1 with an
irreversible mechanism (78).
Competitive inhibitors ofmEH include
oxiranes with a 1-aryl or 1-alkyl sub-
stituent, juvenile hormone epoxides, and
the antiepileptic drug valpromide. Mercury
Table 3. Differential substrates forthe various forms of epoxide hydrolases.
Substrate mEH Cholesterol EH sEH Leukotriene A4 hydrolase
Benzo[a]pyrene 5,6-oxide + - - -
trans-Stilbene oxide - + -
cis-Stilbene oxide + - -
Cholesterol 5,6-oxide - + - -
Leukotriene A4 +a +b
"Product formed is erythro-5,6-dihydroxy-7,9-trans-11,14-cis-icosatetraenoic acid (5,6-DHETE). bproduct formed is
5,12-dihydroxy-6,14-cis-8,1O-trans-icosatetraenoic acid (LTB4).
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and zinc are noncompetitive inhibitors and
cadmium iodide is a potent inhibitor, com-
petitively inhibiting styrene 7,8-oxide
activity (62). Several drugs besides valpro-
mide (cinromide, progabide, valnoctamide,
and valproic acid) were recently found to
be effective inhibitors ofhuman mEH in
vivo (79,80).
Various chalcone oxide derivatives have
been shown to be selective and potent
inhibitors of mouse liver sEH (81). The
inhibition ofsEH by tobacco smoke may
reduce the inactivation of carcinogenic
epoxides in human lung tissues and thus
may increase a person's susceptibility to
lung cancer (82).The sterole imine 5,6a-
imino-5a-cholestan-3p-ol completely
inhibits cholesterol EH, while having no
effect on either mEH or sEH activities. It
has therefore been used diagnostically in





In in vitro assays, most ofthe work done
with GST involves substrates chosen not
because oftheir biological significance but
because their GSH conjugation results in
an optical density change that can be used
in a convenient spectrophotometric assay.
Much of our current understanding of
GSTs relates to these substrates (Table 2).
The most commonly, used substrate is
CDNB, since it is well utilized by most of
the human GSTs, except GSTs included in
the theta class. Other substrates are chosen
because they are relatively specific for a
particular isoenzyme(s) and may be used to
detect or quantify it, e.g., trans-stilbene
oxide which seems to be very specific for
the determination ofGSTM1 (28).
In vitro assays used for the EHs often
involve the use of radiolabeled substrates.
Because ofthe ease and speed with which
this method is carried out, it is mainly
used for routine assays. Examples ofsub-
strates used are styrene 7,8-oxide,
benzo[a]pyrene 4,5-oxide, estroxide, and
trans-ethyl styrene oxide. The advantages
ofusing spectrophotometric assays are that
no radiolabel is necessary and that the
measurement is continuous and therefore
useful for kinetic work. Substrates used are
trans-stilbene oxide and p-nitrostyrene
oxide. To measure enzyme concentrations
in complex mixtures, i.e., cell fractions,
immunological methods are useful due to
their high sensitivity. They have also
proved to be very useful in the detection
ofEH in human serum.
Determination ofGlutathione
Transferases inPlasma
Some problems are associated with activity
measurements of GST in plasma. First,
normal plasma levels ofGST are compara-
tively low and a precise measurement of
activity is difficult to achieve. Second, sev-
eral GSTs bind to a number ofanions such
as bile salts and bilirubin, which will inhibit
the enzymatic activity (24). In liver disease,
when high plasma concentrations ofthese
anions occur, the activity of the GST
released from the hepatocytes into plasma is
inhibited, which will affect the sensitivity of
such tests. Because ofthese problems, assays
ofplasma or serum GST based on activity
measurements have proved to be oflittle
clinical value (84, 85).
Immunoassays have been described and
may allow the precise and specific determi-
nation ofeach ofthe cytosolic GST classes
(86,87). For example, it is possible to
determine a specific GST subunit within a
certain class such as GSTA1 and GSTA2
(87,88). Immunoassay measurements also
determine the GST concentrations even
when they are enzymatically inactive, due
to the presence ofinhibitors such as biliru-
bin or bile salts. It has become apparent
through the use of these immunoassays
that the determination ofGST may have a
clinical role in the diagnosis and monitor-
ing ofpatients with different diseases (89).
A number ofreports have appeared on
the possible use ofthe occurrence ofGSTP
in plasma as a tumor marker. Although a
number of other human tumors express
increased levels ofpi, this seems not to be
a general phenomenon. Therefore, its use




Carbamazepine 10,1 1-epoxide undergoes
almost complete hydrolysis to the 10,11-
transdihydrodiol metabolite in humans.
This reaction is catalyzed by mEH.
Measurement of in vivo mEH activity in
Caucasian subjects after administration of
carbamazepine 10,11-epoxide did not
show outliers indicating enzyme-deficient
phenotypes, and the frequency distribution
was unimodal normal (75). The log meta-
bolic ratio (transdihydrodiol/epoxide)
detected indicated pronounced inhibition
of EH by valpromide and induction by
phenobarbital or phenytoin. A tight range
of in vivo enzyme activities (1.6-fold) was
observed in the healthy Caucasian popula-
tion (75), whereas in vitro mEH activity
has been shown to have an individual vari-
ation ranging from 2.5- to 63-fold,
depending on substrate and the source and
handling ofliver tissue (91).
DistributionofGlutathione
Transferasein HumanTissues
Although the determination of subunit
and/or isoenzyme composition has thus far
been mainly performed with the aid of
(polyclonal) antibodies, a high perfor-
mance liquid chromatography (HPLC)
technique has recently been developed (92)
that shows great promise and in any event
provides a demonstration of the subunit
composition ofhuman tissues.
Polymorphism
Some of the GSTs are polymorphically
expressed (above) with the expression ofa
null allele, GSTM1 (Table 4) and GSTTI.
This makes it possible to detect their
expressions in different individuals either
by phenotyping or genotyping. The phe-
notyping of individuals expressing
GSTM1 can easily be performed in whole
blood, or other tissues available, by using
the specific substrate trans-stilbene oxide
for GSTM1. In the same manner, GSTT1
can be detected in whole blood by using
methyl chloride as substrate. The pheno-
typing procedure enables us to distinguish
between individuals who express the null
allele and those who express the enzyme.
In general, using the phenotyping tech-
nique as a measuring system may involve
some problems such as an inhibitory
effect on the enzyme from endogenous
agents or inappropriate storage of the
sample. To get around these problems, an
ELISA technique might be useful if
antibodies to the specific enzyme studied
are available.
Restriction fragment length polymor-
phism (RFLP) or polymerase chain reac-
tion (PCR) techniques have recently
become very useful tools for genotyping
different enzymes. Following the isolation
ofthe cDNA for GSTM1 and GSTTI, the
PCR technique has been used in many
studies to determine the different geno-
types. This technique may, however, not
allow any evaluation of the level of the
activity expressed in vivo, e.g., between het-
erozygous and homozygous individuals'
expression of the enzyme. On the other
hand, it may be possible to determine a
mutation of an enzyme that results in a
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Table 4. Frequency ofthe GSTM1 null allele in different ethnic groups.
Ethnic or national group No. Gene frequency Reference
Swedish 248 0.732 Seidegard et al. (34)
Finnish 142 0.661 Hirvonen etal. (95)
German 145 0.743 Brockmoller et al. (93)
French 45 0.683 Groppi etal. (94)
Scottish 42 0.673 Hussey etal. (86)
English 49 0.640 Strange etal. (18)
Russian 100 0.697 Afanasyeva and Spitsyn (96)
Saudi Arabian 804 0.749 Evans etal. (97)
Chinese 96 0.765 Board (98)
Indian 43 0.560 Board (98)
Japanese 168 0.691 Harada (99)
Filipino 80 0.814 Evans etal. (97)
Micronesian 37 1.000 Board etal. (38)
Melanesian 49 0.795 Board et al. (38)
Polynesian 49 0.904 Board etal. (38)
defect in enzymatic activity or expression
ofan unstable protein.
Several full-length human mEH DNA
sequences have been cloned (63). The
respective protein sequences deduced from
these DNAs demonstrated less than 2%
variation in human mEH amino acid con-
tent. Despite the similarities, there are
striking interindividual differences in mEH
activity measured in human populations
(91,100). The PCR technique has been
used to identifyvariation in the amino acid
composition in humans. The variation
detected at residues 113 and 139 did not
exert a primary influence on catalytic func-
tion but may affect the stability ofmEH
protein (63). The entire EPHXI gene has
been cloned and sequenced (101). Results
from expression experiments in COS-1 and
HepG2 cells suggested that the human
mEH gene contained aweak core promoter
and that inclusion ofDNA sequences 5'of
the minimal promoter region negatively
regulated constitutive transcription (101).
Genetic factors that regulate sEH have
been studied in normal human lymphocytes
(102). The study included mono- and
dizygotic twins and 100 unrelated male
subjects. The variability ofthe activity was
markedly less within monozygotic than
dizygotic twins. The extent of the
interindividual variation was as much as
11-fold in the 100 subjects. The variation
ofsEH activity in human lymphocytes may
be explained with either monogenic or
polygenic control ofthis mode.
Concluding Remarks
GSTs and EHs are involved in the metab-
olism of a wide range ofdrugs and other
xenobiotics. The enzymes are the products
ofseveral multigene families that are dif-
ferently regulated by a variety of factors.
These genetic and regulatory factors are
therefore likely to play a significant role in
the response ofindividuals to many exoge-
nous as well as endogenous compounds.
Deficiencies of particular enzymes may
alter the susceptibility ofcertain individu-
als to particular compounds. Improved
diagnostic tests that can rapidly identify
enzyme deficiencies are therefore required
to allow their clinical significance to be
fully investigated.
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